» Articles » PMID: 35782615

Mutation Spectrum of Gene in Pediatric Patients with Wilson Disease in Vietnam

Overview
Specialty Endocrinology
Date 2022 Jul 5
PMID 35782615
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Wilson disease (WD) is caused by mutations in the copper-transporting P-type adenosine triphosphatase encoded by the gene. In this study, we screened and identified the mutations among unrelated Vietnamese pediatric patients.

Methods: One-hundred-thirteen pediatric patients with clinically diagnosed WD were recruited. DNA samples were extracted from peripheral blood. Mutations in the gene were identified by Sanger sequencing.

Results: Approximately 98% of the clinically diagnosed WD patients carried mutations A total of 35 different variants were detected, including five novel mutations (L658P, L792P, T977K, IVS4 + 1G > A and IVS20 + 4A > G). Remarkably, this study revealed that S105* was the most prevalent variant (32.27%), followed by L1371P (9.09%), I1148T (7.27%), R778L (6.36%), T850I (5.45%), V176Sfs*28 and IVS14-2A > G (4.55%). Most mutations were located in the exon 2 (37.73%), exon 16 (10.00%), exon 8 (9.55%), exon 20 (9.09%), exon 10 and exon 18 (5.45%), exon 14 (5.00%), exon 13 and intron 14 (4.55%). We developed a streamlined procedure to quickly characterize mutations in the gene in the Vietnamese children, starting with sequencing exon 2 and subsequently to exons 8,10,13-16,18, and 20 to allow quick diagnosis of clinically suspected patients.

Conclusion: The mutational spectrum and hotspots of gene in the Vietnamese population were fairly different from other East Asian populations. A streamlined procedure was developed to screen exon 2 in gene among suspected WD patients to reduce genetically diagnostic cost, to facilitate early detection and intervention in countries with limited resources.

Citing Articles

Navigating the CRISPR/Cas Landscape for Enhanced Diagnosis and Treatment of Wilson's Disease.

Choi W, Cha S, Kim K Cells. 2024; 13(14.

PMID: 39056796 PMC: 11274827. DOI: 10.3390/cells13141214.

References
1.
Koch K, Pena M, Thiele D . Copper-binding motifs in catalysis, transport, detoxification and signaling. Chem Biol. 1997; 4(8):549-60. DOI: 10.1016/s1074-5521(97)90241-6. View

2.
Quick S, Reuner U, Weidauer M, Hempel C, Heidrich F, Mues C . Cardiac and autonomic function in patients with Wilson's disease. Orphanet J Rare Dis. 2019; 14(1):22. PMC: 6348666. DOI: 10.1186/s13023-019-1007-7. View

3.
Schmidt H . Role of genotyping in Wilson's disease. J Hepatol. 2009; 50(3):449-52. DOI: 10.1016/j.jhep.2008.11.008. View

4.
Fatemi N, Sarkar B . Molecular mechanism of copper transport in Wilson disease. Environ Health Perspect. 2002; 110 Suppl 5:695-8. PMC: 1241227. DOI: 10.1289/ehp.02110s5695. View

5.
Ferenci P . Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing. Hum Genet. 2006; 120(2):151-9. DOI: 10.1007/s00439-006-0202-5. View